Christine Bahls

Examining those technology-supported areas that sponsors, CROs, and sites consider the most valuable.

Experts weigh in on efforts to realize incremental gains in using AI to ease systemic ills, such as speeding up study enrollment and reducing the risk for unusable flawed data.

With universal adoption of health literacy best practices slow going over the years, advocates are redefining the term to encompass much more of what health-related communication requires beyond simply words.

A look at the insights and implications surrounding the agency's recommendations on using RWE from electronic health records and medical claims data.

With investors embracing the new regulations, a look at the progress CROs are making in their sustainability efforts

After a period of "fits and starts," large pharma companies are increasingly investing in digital health tools to reach business goals, be they through internal investments or strategic partnerships.

Experts weigh in on the latest advances and adoption trends.

Stepped-up training and real-time application key to avoiding compliance pitfalls.

Experts explore potential paths to achieving buy-in from pharma and regulators.

‘No longer just a cool technology,’ efforts to validate these signals are evolving.

Strategies for intervention—or, ideally, averting potential pitfalls from the onset.

PV is on the road to becoming a leader, not a follower, in leveraging drug lifecycle information for clinical trials and to inform clinical care.

Amidst difficulty in attracting underrepresented populations, industry is searching for ways to include more diverse datasets.

Assessing industry’s use and integration of clinical data science across business.

Summarizing important FDA and EMA revisions issued this year.

Experts gauge threat level for global trials amid staffing and funding issues.

As activity in this space grows, so do the hurdles in moving these products forward.

Experts discuss solving the EHR-compatibility puzzle in point-of-care trials.

New support models range from flexible software platforms, IROs, and DROs.

Technology, talent and specialization add up to a plethora of industry M&As.

Industry set to make choice on whether COVID-19 trials are the new standard.

How COVID-19 blazed a new trail for greater patient inclusion.

Pandemic-forced move to remote monitoring calls for industry-wide collaboration.

eClinical, eSource and EHRs is the journey to the holy grail of data efficiency in clinical trials.